公开(公告)号：US20230330216A1

公开(公告)日：2023-10-19

申请号：US18061831

申请日：2022-12-05

申请人： Novavax, Inc.

发明人： Gale SMITH ,  Michael J. MASSARE ,  Jing-Hui TIAN

IPC分类号： A61K39/215 ,  A61P31/14

CPC分类号： A61K39/215 ,  A61P31/14 ,  A61K2039/545 ,  C12N2770/20034

摘要： Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

公开(公告)号：US20230293667A1

公开(公告)日：2023-09-21

申请号：US17818887

申请日：2022-08-10

申请人： Novavax, Inc.

发明人： Peter M. PUSHKO ,  Yingyun WU ,  Michael J. MASSARE ,  Ye LIU ,  Gale SMITH ,  Bin ZHOU

IPC分类号： A61K39/155 ,  A61K9/00 ,  A61K9/107 ,  A61K39/12 ,  A61K39/39 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/155 ,  A61K9/0019 ,  A61K9/1075 ,  A61K39/12 ,  A61K39/39 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

摘要： The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and; or prevention of RSV infection.

公开(公告)号：US20220080039A1

公开(公告)日：2022-03-17

申请号：US17534659

申请日：2021-11-24

申请人： Novavax, Inc.

发明人： Sarathi BODDAPATI ,  Anushree HERWADKAR ,  Jason WONG ,  Yen-Huei LIN ,  Gale SMITH ,  Jing-Hui TIAN

IPC分类号： A61K39/145 ,  A61P31/16 ,  A61K9/00 ,  A61K9/51

摘要： Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

公开(公告)号：US20210228708A1

公开(公告)日：2021-07-29

申请号：US17170367

申请日：2021-02-08

申请人： NOVAVAX, INC.

发明人： Gale SMITH ,  Michael J. MASSARE ,  Jing-Hui TIAN

IPC分类号： A61K39/215 ,  A61P31/14

摘要： Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

公开(公告)号：US20190224307A1

公开(公告)日：2019-07-25

申请号：US16116990

申请日：2018-08-30

申请人： Novavax, Inc.

发明人： Gale SMITH ,  Ye LIU

IPC分类号： A61K39/205 ,  A61K39/12 ,  C07K14/005

摘要： The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.

公开(公告)号：US20170253861A1

公开(公告)日：2017-09-07

申请号：US15287433

申请日：2016-10-06

申请人： NOVAVAX, INC.

发明人： Gale SMITH ,  Yingyun WU ,  Michael J. MASSARE ,  Peter M. PUSHKO ,  Margaret NATHAN ,  Thomas KORT ,  Robin ROBINSON

IPC分类号： A61K39/12 ,  C12N7/00 ,  A61K39/145 ,  C12N15/86

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55555 ,  C07K14/005 ,  C07K2319/01 ,  C07K2319/03 ,  C12N9/2402 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171 ,  C12N2760/16222 ,  C12N2760/16223 ,  C12N2760/16251 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20051 ,  C12N2800/22 ,  C12Y302/01018

摘要： This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

公开(公告)号：US20220211834A1

公开(公告)日：2022-07-07

申请号：US17398610

申请日：2021-08-10

申请人： Novavax, Inc.

发明人： Jing-Hui TIAN ,  Ye LIU ,  Gale SMITH ,  Gregory GLENN ,  David FLYER

IPC分类号： A61K39/116 ,  A61K39/39

摘要： Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

公开(公告)号：US20210137845A1

公开(公告)日：2021-05-13

申请号：US16629859

申请日：2018-07-24

申请人： NOVAVAX, INC.

发明人： Gale SMITH ,  Ye LIU ,  Jing-Hui TIAN ,  Michael J. MASSARE ,  Sarathi BODDAPATI ,  Gregory GLENN ,  Louis FRIES ,  Iksung CHO

IPC分类号： A61K9/51 ,  A61K39/155 ,  A61P31/14 ,  A61P11/00

摘要： Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

公开(公告)号：US20180133308A1

公开(公告)日：2018-05-17

申请号：US15819962

申请日：2017-11-21

申请人： Novavax, Inc.

发明人： Gale SMITH ,  Ye LIU ,  Jing-Hui TIAN ,  Michael J. MASSARE ,  Sarathi BODDAPATI ,  Erica SHANE ,  Cynthia OLIVER ,  Gregory GLENN

IPC分类号： A61K39/155 ,  A61K9/16 ,  C12N7/00 ,  A61K9/00 ,  A61K39/00

CPC分类号： A61K39/155 ,  A61K9/0019 ,  A61K9/1611 ,  A61K9/1617 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/55555 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2760/14134 ,  C12N2760/14171 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16222 ,  C12N2760/16234 ,  C12N2760/16251 ,  C12N2760/18522 ,  C12N2760/18534

摘要： Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

公开(公告)号：US20180110851A1

公开(公告)日：2018-04-26

申请号：US15608532

申请日：2017-05-30

申请人： NOVAVAX, INC.

发明人： Gale SMITH ,  Rick BRIGHT ,  Peter M. PUSHKO ,  Jinyou ZHANG ,  Kutub MAHMOOD

IPC分类号： A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/58 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2760/16022 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

摘要： The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.